TLDR Certain cancer drugs can cause skin issues like rashes and itching.
The document discussed the "PRIDE" complex, which referred to a range of skin side effects from epidermal growth factor receptor (EGFR) inhibitors used in cancer treatment, such as papulopustules and itching. It reported on two nonsmall cell lung cancer patients treated with gefitinib and erlotinib, who developed skin issues but no systemic toxicities or nail and hair abnormalities. Treatment with benzoyl peroxide, doxycycline, and emollients improved skin lesions within 2 weeks, although hair loss did not improve. The study emphasized the importance of managing these side effects without stopping cancer therapy.
43 citations
,
January 2014 in “Indian Journal of Dermatology” EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.
68 citations
,
January 2014 in “Dermatology research and practice” Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
38 citations
,
February 2012 in “Supportive Care in Cancer” Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.
90 citations
,
August 2006 in “British Journal of Dermatology” PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.
August 2025 in “JEADV Clinical Practice” PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.
August 2024 in “Postgraduate Medical Journal” A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
January 2022 in “Dermatology Review” EGFR inhibitors can cause unusual localized hair growth.
43 citations
,
January 2014 in “Indian Journal of Dermatology” EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.
26 citations
,
October 2018 in “Clinical & Translational Oncology” Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
